Covidien touts EU win for EverFlex stent

January 23, 2013 by MassDevice staff

Medical device maker Covidien wins CE Mark approval in the European Union for its EverFlex self-expanding stent system.

Covidien logo

Medical device company Covidien (NYSE:COV) announced CE Mark approval in the European Union for its EverFlex self-expanding peripheral stent as well as for the accompanying Entrust delivery system.

Covidien plans to roll out the device in Western Europe next month, according to a press release.

Sign up to get our free newsletters delivered right to your inbox.

The EverFlex stent is designed to be easy to control and the Entrust delivery system allows for implantation with a 1-handed maneuver, rather than the traditional 2-handed approach, the company reported. The EverFlex and Entrust devices also come in a variety of sizes to accommodate a range of anatomical and treatment needs.

"Our Entrust technology takes 1-handed delivery to a new level for treating patients with varying conditions," Covidien peripheral vascular general manager and vice president Brian Verrier said in prepared remarks. "Like many Covidien innovations, the design of the Entrust delivery system is based on extensive physician feedback and procedural observation."

Covidien in March 2012 won FDA approval for the EverFlex peripheral vascular stent for treatment in both eh superficial femoral and proximal popliteal artery. The device has been on international markets since 2006.